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The HLA-A*02:01-restricted decapeptide EAAGIGILTV, derived from melanoma antigen
recognized by T-cells-1 (MART-1) protein, represents one of the best-studied tumor asso-
ciated T-cell epitopes, but clinical results targeting this peptide have been disappoint-
ing. This limitation may reflect the dominance of the nonapeptide, AAGIGILTV, at the
melanoma cell surface. The decapeptide and nonapeptide are presented in distinct con-
formations by HLA-A*02:01 and TCRs from clinically relevant T-cell clones recognize
the nonapeptide poorly. Here, we studied the MEL5 TCR that potently recognizes the
nonapeptide. The structure of the MEL5-HLA-A*02:01-AAGIGILTV complex revealed an
induced fit mechanism of antigen recognition involving altered peptide–MHC anchoring.
This “flexing” at the TCR–peptide–MHC interface to accommodate the peptide antigen
explains previously observed incongruences in this well-studied system and has impor-
tant implications for future therapeutic approaches. Finally, this study expands upon the
mechanisms by which molecular plasticity can influence antigen recognition by T cells.
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Introduction
The interaction between the clonotypic αβ TCR and peptide–MHC
(pMHC) governs T-cell mediated immunity toward pathogens and
cancer, and can lead to acute organ transplant rejection and
autoimmune disease. TCR–pMHC complex crystal structures, com-
bined with functional experiments, have demonstrated that the
TCR complementarity determining regions (CDR) loops engage
both the presented peptide and the MHC presentation platform
in a generally conserved diagonal orientation, with the TCR-α
chain position over the MHC-α2 helix and the TCR-β chain over
the MHC-α1 helix [1]. This normal TCR docking orientation typ-
ically positions the somatically rearranged CDR3 loops over the
center of peptide, and the CDR1 and CDR2 loops over the MHC
helices, enabling the TCR to recognize antigen in a peptide-specific
mode [2]. Despite this conserved binding geometry, the interac-
tion between the TCR and pMHC can be highly flexible, or even
reversed [3–5]. This flexibility is likely to be part of the mech-
anism that enables T cells to cross-react with multiple different
antigens [6–13], a property that is required for effective protec-
tive immunity [14, 15].
Here, we investigated the Melan-A (melanoma antigen
A)/MART-1 (melanoma antigen recognized by T-cells-1) protein
that has been the focus of a number of clinical approaches
designed to employ T-cells for targeting melanoma [16–21]. It
has been previously shown that, in the context of HLA-A*02:01,
two overlapping peptides are recognized by CD8+ T cells: the
MART-127-35 nonapeptide AAGIGILTV (A2-AAG); and the MART-
126-35 decapeptide EAAGIGILTV (A2-EAA) [17, 22]. However,
despite A2-AAG being the dominant peptide on the surface of
tumors [22], most published T-cell clones recognize A2-EAA more
strongly than A2-AAG [17, 23, 24]. This has fueled a number
of investigations that have defined the presentation mode of A2-
AAG, A2-EAA, and MHC anchor modified “heteroclitic” versions
of the peptides, most notably ELAGIGILTV (altered residue in
bold text) [17, 25, 26]. Other investigations have focused on the
mechanisms of TCR recognition in this system [24, 27–29]. These
studies have shown that the clinically targeted decapeptide, the
minority species on tumors [22], is presented in a distinct “bulged”
conformation by HLA-A*02:01, compared to the “stretched” con-
formation of the nonapeptide [25, 26]. Concomitant with the lack
of clinical success targeting these antigens, most TCRs recognize
the nonapeptide with relatively weak affinities compared to the
reported natural range for TCR interactions with cognate pMHC
(KD = 0.13–270 μM) [30–32]. Structural studies have revealed
that two TCRs used in a clinical setting, DMF4 and DMF5, have to
make structural compromises when interacting with the nonapep-
tide [24]. In accordance, Blankenstein and colleagues recently
showed that T cells, transduced with a clinically relevant TCR,
induced rejection of tumors expressing the analog ELAGIGILTV,
but not native AAGIGILTV, Melan A/MART-1 epitope [33]. Con-
sequently, there is a need to understand the seemingly complex
molecular rules that govern T-cell antigen recognition in this
system so that effective therapies can be developed. We previously
identified a T-cell clone (MEL5) [27] that can potently recognize
A2-AAG, consistent with the relatively strong binding affinity
(KD  14 μM) for the MEL5-A2-AAG interaction [23].
Here, we solved the structure of the MEL5 TCR in complex
with A2-AAG to uncover the mechanisms governing the effective
recognition of this tumor antigen. Unexpectedly, we found that
MEL5 recognition of A2-AAG was governed by a “molecular
switch” in the peptide. Other published TCRs do not induce this
conformational alteration in the A2-AAG peptide [24], providing
a possible reason for why non-MEL5-like T cells recognize this
melanoma antigen poorly. Importantly, this finding expands
our understanding of the mechanisms by which the TCR–pMHC
interface can “flex” to accommodate optimal antigen recognition.
Results
The MEL5 and α24β17 TCRs induce a peptide anchor
residue switch in A2-AAG
We have previously shown that the MEL5 TCR can bind to A2-AAG
with a stronger affinity (KD = 14.2 μM) [23] than other published
TCRs (average KD = 101 μM; Table 1). This approximately
sevenfold average difference in TCR affinity is likely to have sub-
stantial benefits for recognition of A2-AAG at the melanoma cell
surface [34]. To confirm the potential benefits of the MEL5 TCR,
we transferred MEL5, MEL187.c5, and DMF4 [16] TCRs into pri-
mary CD8+ T cells for comparison. In order to avoid bias induced
by differences in the efficiency of lentiviral transduction, our
constructs encoded a surface-expressed marker gene (rat CD2),
which was used to isolate TCR transduced T-cells and to monitor
their purity. MEL5 and DMF4 TCRs showed similar sensitivity
to the Melan-A/MART-1 decapeptide (EAAGIGILTV) in terms of
MIP-1β secretion; conversely, the sensitivity of MEL5 TCR to the
nonapeptide AAGIGILTV was 100× higher than the sensitivity
of DMF4 TCR (Fig. 1A). The increased reactivity of MEL5 TCR
toward the AAGIGILTV epitope, compared to DMF4 TCR, was
further supported by TNF production (Fig. 1B, left panel; Sup-
porting Information Fig. S1A). In line with these findings, MEL5
TCR was capable of mounting a significantly stronger response
to HLA-A*02:01 positive melanoma cell lines than DMF4, while
remaining inert to HLA-A*02:01 or Melan-A negative cancer
cells (Fig. 1B, right panel; Supporting Information Fig. S1B).
MEL187.c5 TCR induced only a weak response even to the het-
eroclitic variant ELAGIGILTV (Supporting Information Fig. S2),
despite favorable biophysical properties (Table 1). Due to lack
of reactivity, we did not include MEL187.c5 TCR in subsequent
experiments. The gating strategy is shown in Figure 1C.
The superior recognition of AAGIGILTV peptide and tumor
targets by MEL5 TCR suggests that it might make a good clinical
candidate for recognizing melanoma cells. To understand the
structural basis for this improved recognition, we solved the
structure of MEL5-A2-AAG using X-ray crystallography (Support-
ing Information Table S1). Unexpectedly, we observed partial
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Table 1. MEL5, MEL187.c, DMF4, DMF5, and α24β17 binding affinities (KD): A2-AAG versus A2-EAA versus A2-ELA
TCR binding affinity KD
Ligand MEL5 MEL187.c5 DMF4 DMF5 α24β17
A2-AAG 14.2 ± 0.7 μM [23] 94 ± 22 μM [23] 170 ± 11 μM [24] 40 ± 2 μM [24] 26.2 nM
A2-EAA 8.4 ± 0.2 μM [23] 42 ± 0.3 μM [23] nr nr 0.75 nM [29]
A2-ELA 18 ± 1 μM [27] 18 ± 0.1 μM [23] 29 ± 4 μM [24] 5.6 ± 1.5 μM [24] 0.6 nM [29]
nr, not reported.
occupancy in the electron density map of the peptide at the
N-terminus, representing two different conformations, supported
by omit map and density analysis (Fig. 2). In one form, the AAG
peptide was presented in a “stretched” (A2-AAGstr) conformation
compared to the “bulged” conformation (A2-AAGbul) observed
in the alternative form. To confirm this unusual observation, we
investigated the binding mode of a previously published high
affinity variant of MEL5, the α24β17 TCR [29]. The α24β17 TCR
bound to A2-AAG and A2-EAA with nanomolar affinity (KD = 26.2
and 0.75 nM, respectively; Table 1) and the structure of this
TCR in complex with A2-AAG (Supporting Information Table S1)
revealed the same partial occupancy in the electron density of the
peptide (Fig. 2). The overall binding mode of the MEL5 (Fig. 3A)
and α24β17 TCRs in complex with A2-AAG was similar to the
MEL5-A2-EAA complex. This was reflected by similar crossing
angles of 48° and 42.3° and buried surface areas (BSAs) of
2200 and 2600 A˚ for MEL5 and α24β17 TCRs, respectively, in
complex with A2-AAG (Table 2), compared to a crossing angle of
46.9° and BSA of 2366 A˚ for MEL5-A2-EAA [28].
Further inspection of the peptide presentation mode revealed
that the conformation observed in the TCR-A2-AAGbul structures
required an anchor residue shift at the N-terminus of the peptide,
utilizing Ala1 as the primary MHC anchor in the B pocket, rather
than Ala2 as in the TCR-A2-AAGstr structures (Fig. 3B). Indeed, the
Cα of Ala1 shifted 4.7A˚ in order to mediate this binding mode
in the structures with both WT and enhanced affinity TCRs. This
anchor residue shift left the HLA-A*02:01 A-pocket unoccupied
(Fig. 3C). The only other example in humans where an empty
A-pocket has been observed was in the unnatural, heteroclitic non-
apeptide A2-LAGIGILTV, in which Ala1 was substituted with Leu,
an optimal residue for binding to the B-pocket in HLA-A*02:01 to
artificially induce this binding mode. Substitution of the position
1 Ala residue for Leu enabled the peptide to anchor at residue one,
forming a conformation similar to that of A2-EAA [25]. Interest-
ingly, the LAGIGILTV nonapeptide was recognized more strongly
than AAGIGILTV by multiple TCRs, demonstrating the importance
of a central EAAGIGILTV-like peptide bulge during T-cell recogni-
tion [25]. The switch in anchor residue from Ala2 to Ala1 in the
A2-AAGbul structure enabled peptide residue Gly5 to swing 1.7A˚,
compared to A2-AAGstr, into an identical position compared to A2-
EAA. The ability of MEL5, but not other TCRs, to bind to A2-AAG
in an A2-EAA-like conformation probably explains why MEL5 was
better able to recognize the immunodominant MART-1/Melan-A
nonapeptide compared to other published TCRs.
MEL5 captures A2-AAG in a different conformation
than other TCRs
The two different conformations of the AAG peptide (Fig. 4A and
B) were similar to that of the AAG nonapeptide and EAA decapep-
tide observed in other studies. In the A2-AAGstr conformation, the
AAG peptide closely resembled that observed for the unbound
pMHC, and the conformation present in the co-complex struc-
tures with the DMF4 and DMF5 TCRs (Fig. 4C and D). In the
A2-AAGbul form, the AAG peptide adopted a conformation similar
to the A2-EAA decapeptide that is better recognized by all other
TCRs currently described. Structural alignment analysis supported
this observation, demonstrating a closermatch between A2-AAGbul
and A2-EAA by root mean square deviation (r.m.s.d. = 0.346
A˚) than A2-AAGbul and unbound A2-AAG (r.m.s.d. = 2.203 A˚;
Fig. 4E). A2-AAGstr and A2-AAG in complex with DMF4 and
DMF5 all aligned more closely with unbound A2-AAG (average
r.m.s.d. = 0.523 A˚) than A2-EAA (average r.m.s.d. = 1.848 A˚;
Fig. 4F–H). This unique recognition mechanism likely contributes
to the stronger comparative affinity between MEL5 and A2-AAG
compared to other TCRs reported.
MEL5-like TCRs utilize an A2-EAA-like peptide
binding mode when interacting with A2-AAG
Previous co-complex structures of the DMF4 and DMF5 TCRs
have demonstrated that A2-AAG is recognized in a “stretched”
conformation compared to the “bulged” presentation mode of
the decapeptide [24]. This is perhaps not surprising as analysis
of the peptide–MHC interaction showed that there were more
contacts between HLA-A*02:01 and AAGstr (122 contacts) than
for AAGbul (107 contacts). This was mainly due to the unoccupied
A pocket and thus the loss of contact between the MHC helices
and Ala1 for AAGbul. Thus, A2-AAGstr is probably more stably
presented than A2-AAGbul (consistent with the unbound A2-AAG
structure [25, 35]). DMF4 underwent the largest adjustment
when binding to A2-AAG (consistent with the weaker binding
affinity of KD = 170 μM), with the TCR orienting differently
compared to the interaction with the position 2 substituted
heteroclitic decapeptide, HLA-A2-ELAGIGILTV (A2-ELA). DMF5
bound to A2-AAG in the same conformation as for A2-ELA,
probably contributing to the stronger comparative binding affinity
(KD = 40 μM), but still made substantial adjustments to peptide
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 1. Functional assessment of the response toward HLA-A*02:01/MART-1 epitopes mediated by MEL5, MEL187.c5, and DMF4 TCRs. (A) MIP-1β
release, in response to titrated concentrations of MART-1 decamer (EAAGIGILTV) and nonamer (AAGIGILTV) peptides presented by T2 cells, by T-
cells transducedwith theMEL5, MEL187.c5, or DMF4 TCRs. Quantification of secretedMIP-1βwas performed by ELISA. Experiments were performed
in duplicate, using PBMCs from three different donors, transduced with MEL5, MEL187.c5, or DMF4 TCRs. Error bars denote SEM from two biological
replicates (two independent experiments) using the TCR-transduced T cells from one representative donor. (B) TNF alpha production in response
to MART-1 decamer and nonamer peptides presented by T2 cell line (left panel) or endogenously processed and presented epitopes by cancer cell
lines. Experiments were performed in duplicate, using PBMCs from three different donors, transduced with MEL5, MEL187.c5, or DMF4 TCRs. Mean
percentage and SD of TNF+ events among viable CD8+ (and rat CD2+ where applicable) cells from three donors is shown. Two sided Student’s
t-test; ns, not significant; p > 0.05; ***p < 0.001. (C) Gating strategy for assessing the functional response of TCR transduced cells to cancer cells or
exogenously supplied agonist peptides. Gating strategy for untransduced (top panel) or TCR transduced (bottom panel) T cells are shown. Rat CD2
is a marker of TCR transduction. Numbers on contour plots indicate the percentage of events in marked gates.
contacts. Both DMF4 and DMF5 had three less hydrogen bonds
with the AAG peptide compared to A2-ELA. In contrast, MEL5
bound to A2-AAG in a virtually identical conformation to A2-ELA
and A2-EAA and maintained a very similar peptide interface,
only losing substantial contacts with Glu1 (not present in the
nonapeptide) (Supporting Information Table S2). MEL5 and
α24β17 interacted with A2-AAGbul and A2-AAGstr in a similar
fashion, both focusing on the solvent exposed “GIGI” motif in
the center of the peptide and making four hydrogen bonds and
multiple van der Waals (vdWs) contacts through TCR residues
αGln31 and βLeu98 (Fig. 5A–D). This was reflected by a relatively
small r.m.s.d. when aligning the AAGbul peptide bound to MEL5
or α24β17 TCRs (r.m.s.d. = 0.335), or the AAGstr peptide bound
to MEL5 or α24β17 TCR (r.m.s.d. = 0.538). The main differences
in peptide interactions were observed at the N-terminus of the
peptide forms, in which additional contacts were formed between
MEL5 αGln31 and Ala2, and α24β17 αGln31 and Ala1. Despite
the similarity in number of contacts between the two forms of the
peptide with MEL5, both BSA and surface complementarity were
higher for MEL5-A2-AAGbul (655 A˚2 and 0.634) compared to
MEL5-A2-AAGstr (545 A˚2 and 0.579), suggesting that A2-AAGbul
could be a more favorable conformation for MEL5 binding.
Interestingly, MEL5 bound to A2-AAG with a slightly stronger
affinity than to A2-ELA (Table 1), demonstrating the superior abil-
ity of MEL5 to recognize the natural MART-1/Melan-A nonapep-
tide compared to the heteroclitic decapeptide that has been used
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
1056 Florian Madura et al. Eur. J. Immunol. 2019. 49: 1052–1066
Figure 2. MEL5-A2-AAG and α24β17-A2-AAG omit map analysis. (A and B) In all panels HLA-A*02:01 is colored in grey cartoon, with AAGIGILTV
presented in the “bulged” conformation (A2-AAGbul) colored in green sticks, or presented in the “stretched” (A2-AAGstr) conformation colored in
purple sticks. From left to right: first panel is MEL5-A2-AAGbul, second panel is α24β17-A2-AAGbul, third panel is MEL5-A2-AAGstr and last panel is
α24β17-A2-AAGstr. (A) Difference electron density omit maps showing a side view of the peptide in each complex in which the model was refined
in the absence of the peptide with difference density contoured at 3.0 σ (positive contours colored green, negative contours colored red). (B) 2Fo-Fc
peptide electron density maps at 1 σ (shown in blue) showing a side view of the peptide in each complex. These data were generated from a single
data set derived from X-ray crystallographic analysis.
in vaccine trials [16–21]. This difference in affinity was consistent
with the extra hydrogen bond formed between MEL5 βLeu98 and
A2-AAG Ile6, compared to the MEL5-A2-ELA complex [27].
An identical network of TCR–MHC contacts supported the
interactions with the A2-AAGbul and A2-AAGstr versions of the
peptide for both MEL5 and α24β17 TCRs. Guided by interac-
tions with all three of the restriction triad residues (Arg65, Ala69,
and Gln155), MEL5 formed an additional hydrogen bond and salt
bridge with MHC residues Thr163 and Glu166, respectively. The
α24β17 TCR also contacted all three restriction triad residues,
but formed several new interactions, primarily with the HLA α1
helix, mediated mainly through residues mutated during the affin-
ity maturation process (Fig. 5E–H). These interactions included
an extra salt bridge between αAsp93 and αArg65, and three new
hydrogen bonds between TCR residues βPro52 and βPhe53, and
MHC residue Gln72 compared to the MEL5 TCR. In total, α24β17
made one additional electrostatic interaction and four additional
vdWs contacts with the peptide, but three additional electrostatic
interactions and 56 additional vdWs contacts with the MHC sur-
face compared to the MEL5 TCR (Table 2). Thus, in agreement
with our previously published data comparing natural and modi-
fied high affinity TCRs [29, 36, 37], the high affinity interaction
between α24β17 and A2-AAG (KD = 26.2 nM) was mainly medi-
ated through extra contacts directly involving mutated residues.
Thermodynamic, NMR, and modeling analysis
support an anchor residue shift during MEL5 binding
Although the observations from the crystal structure were con-
sistent with the ability of MEL5 to bind to A2-AAG with stronger
affinity than for other TCRs, we performed thermodynamic
experiments to provide additional evidence for the AAG anchor
residue shift upon MEL5 TCR binding. First, we analyzed changes
in standard free energy (G°), enthalpy (H°), and entropy
(S°) for MEL5 and α24β17 interacting with A2-AAG versus A2-
EAA (Fig. 6A). We have previously shown that the MEL5-A2-EAA
interaction is not characterized by an anchor residue shift in the
peptide, but still involves peptide side chain movement at Glu1
compared to the MEL5-A2-ELA complex [27, 28]. This movement
probably contributed toward a larger entropic penalty during bind-
ing (TS°  −7.2 kcal/mol) compared to MEL5-A2-ELA (TS° 
8.4 kcal/mol), that was overcome through the formation of new
electrostatic interactions (in part mediated by the movement a
Glu1 in the MEL5-A2-EAA structure). Although the standard free
energies were similar for MEL5-A2-EAA (G° = −6.8 kcal/mol)
and MEL5-A2-AAG (G° = −6.6 kcal/mol), MEL5 used dif-
ferent energetic strategies to bind to each peptide (Fig. 6A).
Whereas the binding to A2-EAA was entropically unfavorable
(TS° = −7.2 kcal/mol), the binding to A2-AAG was slightly
entropically favored (TS° = 0.49 kcal/mol). This is consistent
with the extra mobility observed in the peptide in the MEL5-
A2-AAG structure, which would result in a lower disorder to
order transition during ligand engagement. The thermodynamics
were also consistent with the interaction interface, with the
MEL5-A2-EAA complex forming more bonds (12 electrostatics
and 104 vdW’s, compared to nine electrostatics and 75 vdW’s for
MEL5-A2-AAG) and having a more favorable enthalpic change
(H° = −14 kcal/mol), compared to the MEL5-A2-AAG complex
(H° = −6.1 kcal/mol). The thermodynamic analysis of the
α24β17 TCR was consistent with these observed differences
in A2-EAA versus A2-AAG TCR interactions, demonstrating a
more favorable entropic component (TS° = 23.1 kcal/mol and
TS° = 47.1 kcal/mol) and less favorable enthalpic component
(H° = 11.1 kcal/mol and H° = 36.3 kcal/mol) for binding to
A2-EAA and A2-AAG, respectively. Although α24β17 is a modified
high affinity TCR, these data represent the most extreme unfavor-
able entropic component observed for a TCR-pMHC interaction
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 3. MEL5 and α24β17 TCRs induce a peptide anchor residue
switch in A2-AAG. (A) Overall conformation of the MEL5 (α-chain green
cartoon, β-chain cyan cartoon) in complex with HLA-A*02:01 (grey car-
toon) presenting the AAG peptide (green, purple, and black sticks). (B)
Top: the peptide anchor residue switch in the AAG peptide is depicted
with the residues that shift in the AAGbul form in green sticks, and
the residues that shift in the AAGstr form in purple sticks. Bottom:
expanded view of the N-terminal of the AAG peptide with the shift in
position of Cα of alanine residue 1 indicated by the yellow arrow. (C) Top
down view of the AAGIGILTV peptide binding to theHLA-A*02:01 groove
(grey) presented in the ‘bulged’ conformation (A2-AAGbul) colored in
green sticks, or presented in the “stretched” (A2-AAGstr) conformation
colored in purple sticks. In bulged form (left), peptide residue Ala1 Cα
moves 4.7A˚ compared to the stretched form (right) (highlighted using
yellow dashed line) leaving the A-pocket unoccupied. These data were
generated from a single data set derived from X-ray crystallographic
analysis.
(range observed for natural TCR-pMHC interactions: H° = −30
to 12 kcal/mol; TS° = −24 to 8.4 kcal/mol) [27, 38], extending
the range of energetic strategies that can be utilized by the TCR
scaffold.
Next, we examined the conformational consequences of MEL5
binding to A2-AAG in solution using NMR spectroscopy (Fig. 6B).
The AAG peptide was labeled with 13C at Ala1 (which underwent
the largest movement between the AAGbul and AAGstr structures)
and Val9 (which did not move upon MEL5 binding) and exam-
ined by NMR alone and in the presence of the MEL5 TCR. 1D 1H
spectra showed that proteins were folded under both conditions.
In the absence of MEL5, each labeled methyl group gave a single
resonance, with approximately equal intensities to one another.
On addition of MEL5, all labeled methyl groups showed chem-
ical shift perturbations, and multiple resonances were seen for
each methyl group. However, while the Val9 methyl groups each
gave one major and one minor resonance (consistent with there
being a small amount of A2-AAG binary complex still present), the
Ala1 methyl group gave two resonances of approximately equal
intensity to one another, and half the intensity of the Val9 methyl
peaks. The observation of two resonances of 50% intensity mir-
rors our findings in the crystal structure in which the AAGbul and
AAGstr forms of the peptide were both present when in complex
with MEL5. This suggests that, in the presence of MEL5, the Ala1
methyl group experiences two different molecular environments
while the Val9 methyl groups only experience one, consistent with
the X-ray structure.
Finally, we investigated the stability of the AAG peptide in
complex with MEL5 and DMF4 using a computational approach,
FIRST, as described in the methods (Supporting Information
Fig. S3A and B). This analysis demonstrated that the AAG
peptide was more flexible when bound to MEL5 compared to
DMF4 (Fig. 6C), particularly at the N-terminus (the portion of the
peptide that shifted when binding to MEL5). The first two residues
of the peptide (AA) lost rigidity at cutoffs of –0.07 kcal/mol or
smaller in the MEL5 complex, compared to the DMF4 complex
where the same residues remained rigid down to a cutoff of
–0.27 kcal/mol. In contrast, the C-terminal portion of the AAG
peptide in both the MEL5 and DMF4 structures was still rigid
Table 2. Summary of co-complex structures of MEL5-A2-AAG and α24β17-A2-AAG
Contacts MEL5-A2-AAGbul MEL5-A2-AAGstr α24β17-A2-AAGbul α24β17-A2-AAGstr
TCR/pMHCa) 8/1/75 8/1/74 11/2/136 11/2/132
TCRα-pMHCa) 3/1/31 3/1/30 6/1/58 6/1/55
TCRβ-pMHCa) 5/0/44 5/0/44 6/0/68 6/0/77
TCR/peptidea) 4/0/27 4/0/26 5/0/32 5/0/28
TCR/MHCa) 4/1/48 4/1/48 6/2/104 6/2/104
BSAb) (A˚2) 1620/655/2275 1625/545/2170 1944/682/2626 1951/662/2613
SCc) (%) 53.8/63.4/56.8 53.8/57.9/53.5 73.2/61.1/70.9 73.2/42/62
Crossing angle (°) 48.0 48.0 42.3 42.3
a)Number of hydrogen bonds (H-bond) (<3.4 A˚)/salt bridges (<3.4 A˚)/van der Waals (vdW) (4 A˚) contacts calculated with CONTACT program from
the CCP4 package [66].
b)Buried surface area (BSA) (A˚2) of TCR–MHC/TCR–peptide/TCR–pMHC calculated with PISA [76].
c)Shape complementarity (SC) (%) of TCR–MHC/TCR–peptide / TCR–pMHC calculated with SC program from the CCP4 package [66].
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
1058 Florian Madura et al. Eur. J. Immunol. 2019. 49: 1052–1066
A B C
MEL5-A2-AAGbul
D
α β α β α β α β
MEL5-A2-AAGstr DMF4-A2-AAG DMF5-A2-AAG
E F G H
Un
bo
un
d 
A2
-A
AG
Un
bo
un
d 
A2
-E
AA
2.203 1.037              0.260 0.272
0.346 1.442 2.135                 1.967
Figure 4. MEL5 captures A2-AAG in a unique conformation compared to other reported TCRs. (A and B) Upper panel shows the MEL5 TCR (α-chain
green and β-cyan cartoon) bound to HLA-A*02:01 (grey cartoon) in complexwith (A) AAGIGILTV presented in the “bulged” conformation (A2-AAGbul)
colored in green spheres and (B) AAGIGILTV presented in the “stretched” (A2-AAGstr) conformation colored in purple spheres. The lower panel
shows the side view of the peptide conformation in sticks (colors as in the upper panel). (C) Upper panel shows the DMF4 TCR (sand and orange
cartoon) bound to HLA-A*02:01 (grey cartoon) in complex with AAGIGILTV (purple spheres). The lower panel shows the side view of the peptide
conformation in sticks (colors as in the upper panel). (D) Upper panel shows the DMF5 TCR (yellow and brown cartoon) bound to HLA-A*02:01 (grey
cartoon) in complex with AAGIGILTV (purple spheres). The lower panel shows the side view of the peptide conformation in sticks (colors as in
the upper panel). (E–H) Superpositions of A2-AAG in complex with TCR (colored as in A–D, shown in sticks) with unbound A2-AAG (upper panel,
light blue sticks) or unbound A2-EAA (lower panel, yellow sticks). The number below each peptide represents the root mean square deviation for
each superposition. The circles show the main region where differences in peptide conformation are apparent between the TCR-A2-AAG complex
and unbound pMHCs. (E) MEL5-A2-AAGbul, (F) MEL5-A2-AAGstr, (G) DMF4-A2-AAG, and (H) DMF5-A2-AAG. These data were generated from a single
data set derived from X-ray crystallographic analysis.
at cutoffs around –1.5 kcal/mol. Thus, these analyses support
our other observations demonstrating that the MEL5 TCR, but
not other A2-AAG/A2-EAA specific TCRs, can induce N-terminal
flexibility in the AAG peptide that enhances TCR engagement.
Discussion
Despite over a decade of research, therapies directed against the
HLA-A*02:01 restrictedMART-1/Melan-A26/27-35 peptide antigens
have had limited success [39, 40]. Approaches that employed a
heteroclitic version of the decapeptide with the position 2 Ala sub-
stituted for Leu (ELAGIGILTV) probably failed because the anchor
residue modification at peptide residue 2 altered the TCR recog-
nition platform [28, 41], leading to selection of T cells that did
not recognize the native antigen effectively [18, 40]. Furthermore,
although the majority of MART-1/Melan-A specific CD8+ T cells
preferentially recognize the decapeptide rather than the nonapep-
tide [17, 24], theMART-1/Melan-A27-35 nonapeptide, AAGIGILTV,
has been identified as the immunodominant epitope on the surface
of tumors [22]. Subsequently, TCRs selected against the decapep-
tide have generally been found to recognize the nonapeptide
poorly [24, 41], probably because the nonapeptide forms a dif-
ferent conformation when presented by HLA-A*02:01 compared
to the decapeptide [25, 26], adding a further explanation for the
poor outcome of therapies directed against this antigen.
To shed additional light on this therapeutically important
system, we focused on the MEL5 TCR that can bind to A2-AAG
with stronger affinity than any other TCR reported [23, 24].
We examined the structural and thermodynamic properties of
the MEL5-A2-AAG interaction (and used a high affinity version
of the MEL5 TCR, α24β17, to validate our observations) and
compared our findings to DMF4 and DMF5 recognition of
MART-1/Melan-A26/27-35. Our data revealed that recognition of
A2-AAG by MEL5, but not other published TCRs, involved a novel
peptide anchor residue switch, enabling the peptide to present a
bulged form, anchored with Ala1 of the peptide within the MHC
B-pocket. Our data are consistent with the recognition patterns
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Figure 5. MEL5-like TCRs can utilize an A2-EAA-like peptide binding mode when interacting with A2-AAG. (A–D) TCR interactions with the AAG
peptide. (E–H) TCR interactions with HLA-A*02:01. In all panels, MEL5 is colored in green and cyan cartoon, α24β17 is colored in dark green and dark
purple cartoon, HLA-A*02:01 is colored in grey cartoon, AAGbul is colored in green sticks, and AAGstr is colored in purple sticks. Black dotted lines
represent vdW contacts (4 A˚) and red dotted lines represent H-bonds or salt bridges (3.4 A˚). (A) Main interactions between MEL5 and AAGbul.
(B) Main interactions between MEL5 and AAGstr. (C) Main interactions between α24β17 and AAGbul. (D) Main interactions between α24β17 and
AAGstr. (E) Main interactions between MEL5 and HLA-A*02:01 α1 domains. (F) Main interactions between α24β17 and HLA-A*02:01 α1 domains.
(G) Main interactions between MEL5 and HLA-A*02:01 α2 domains. (H) Main interactions between α24β17 and HLA-A*02:01 α2 domains. These data
were generated from a single data set derived from X-ray crystallographic analysis.
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Figure 6. Thermodynamic, NMR, and modeling analysis support an anchor residue shift during MEL5 binding. (A) For MEL5, KD values were
measured in duplicate (separate experiments) at 5, 10, 15, 20, 25, and 30°C using equilibrium analysis by SPR. For α24β17, KD values were measured
in duplicate (separate experiments) at 5, 7, 12, 15, 19, 22, 25, 30, and 32°C using single cycle kinetic analysis by SPR; representative data from one of
these experiments is plotted. From these data, the binding free energies (G = RT ln KD) were plotted against temperature and the thermodynamic
parameters (H° and TS°) were calculated according to the nonlinear van’t Hoff equation (RT ln KD = H° – TS° + Cp°(T – T0) – TCp° ln (T/T0))
for MEL5-A2-EAA, MEL5-A2-AAG, α24β17-A2-EAA, and α24β17-A2-AAG. (B) Solvent-suppressed 1H (top) and methyl-region 1H-13C HSQC NMR
spectra of an equimolar mixture of A2-A(13C3)AGIGILTV and A2-AAGIGILTV(15N,13C5) in the absence (red) and presence (black) of the MEL5 TCR.
Relative integrals for each HSQC peak are indicated on the spectra. These data were generated from a single data set derived from NMR analysis.
(C) FIRST analysis of AAG peptide stability for the MEL5-A2-AAG (left) and DMF4-A2-AAG (right) complexes. The colors indicate the simulated
energy (kcal/mol) required to destabilize different parts of the peptide with most unstable residues colored red and most stable residues colored
blue. A more detailed key of the energy cutoffs is shown in the figure. Below is the stripy plot analysis, which reports the distribution of rigid
clusters in the structure. The AAG peptide (full plot shown in Supporting Information Fig. S3) is shown in the context of each complex. Peptide
residues 1–9 are shown from bottom to top. Red bars indicate a rigid residue. Disappearance of red bars with increased simulated bond energy is
shown from left to right. These data were generated from a single data set derived from X-ray crystallographic analysis.
of the heteroclitic nonapeptides, LAGIGILTV and ALGIGILTV. The
LAGIGILTV peptide that forms a bulged conformation similar to
A2-EAA, (because the Ala1Leu mutation forces the peptide to
anchor at position P1 in the B pocket), is recognized optimally
compared to ALGIGILTV [17], which is forced into the stretched
conformation [25]. Thus, unlike the DMF4 and DMF5 TCRs,
where the complex structures with A2-ELA and A2-AAG were out
of alignment at Ile4 and Ile5, MEL5 could stabilize the bulged
nonapeptide conformation, mimicking the A2-ELA, A2-EAA, and
A2-LAG peptide conformations upon TCRs recognition.
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The peptide anchor residue shift in the MEL5-A2-AAG and
α24β17-A2-AAG structures was further supported by the thermo-
dynamic and NMR experiments. In both cases, thermodynamic
analyses of the TCR-A2-AAG complexes revealed an entropically
more favorable interaction than for the TCR-A2-EAA complexes.
Further, chemical shift analysis by NMR demonstrated that, on
addition of MEL5, two resonances of equal intensities were appar-
ent for the labeled Ala1 residue (where we observed the anchor
residue shift in the structure), consistent with the existence of two
different conformations for this residue represented by the AAGbul
and AAGstr forms of the peptide in the crystal structure. Lastly,
FIRST rigidity analysis was also consistent with our findings,
demonstrating greater peptide instability at the N-terminus of
the AAG peptide when bound to MEL5 compared to the DMF4
TCR. The mechanism that drives the conformational change we
observed in the AAG peptide when bound to MEL5, and not other
TCRs, remains unclear. We have previously shown the importance
of Gln at position 31 in the CDR1 loop of MEL5 (encoded by
TRAV12-2) for recognition of the A2-EAA and A2-ELA decamer
peptides [27, 28]. However, although DMF4 lacks this residue
(encoded by TRAV35), the DMF5 TCR shares the TRAV12-2 gene
usage and uses a very similar binding mode, compared to MEL5,
to engage both the AAG nonomer and EAA decamer peptides.
We speculate that fine differences in the dynamics of the CDR
loops of MEL5, compared to DMF4 and DMF5 TCRs, enable its
unique binding mode, further demonstrating the complexity of
the mechanisms that underpin TCR recognition of pMHC.
These findings have implications for the mechanisms that
control the high degree of T-cell cross-reactivity recently
reported [7–13]. One key idea, which has arisen through obser-
vations made through molecular experimentation using X-ray
crystallography and other techniques, is that the TCR–pMHC
interaction is highly flexible [3, 42, 43]. Indeed, studies to
date have revealed three main mechanisms of conformational
flexibility at the TCR-pMHC interface that likely play a key role in
T-cell antigen recognition. First, it has been shown that the TCR
CDR loops can flex upon binding [3]. The types of loop shift can
be placed into three major classes: (i) loop remodeling facilitated
by multiple ϕ/ψ bond angle changes; (ii) hinge-bending motions;
and (iii) rigid-body shifts [3]. Second, movements of the MHC
α-helices have been described in which the α-helices flanking
the peptide-binding groove can shift upon TCR binding. This
has been observed in the recognition of H-2Kb-RGYVYQGL by
the BM3.3 TCR [44, 45] and HLA-DR2a-VHFFKNIVTPRTPG by
the 3A6 TCR [46]. In both cases, rigid-body shifts of 1 A˚ were
distributed across both the α1 and α2 helices [3]. More radical
HLA-A*02:01 α2-helix conformational changes have also been
observed upon the recognition of A2-MLWGYLQYV by the A6 TCR
in which a conformational “switch” occurred at the hinge of the
short and long helical elements that altered the pivot of the short
arm and extended the long arm of the α2-helix [47]. Third, there
have been reports that TCR binding can induce conformational
changes in the solvent exposed central peptide residues, mediating
TCR docking and T-cell recognition [48]. Small backbone shifts
have been observed upon recognition of the A2-LLFGYPVYV and
A2-SLLMWITQC peptides presented by HLA-A*02:01 [49–52].
More dramatic peptide movements have been reported for binding
of the ELS4 TCR to HLA-B*35:01-EPLPQGQLTAY, with a large
shift of 5 A˚ occurring in the center of the peptide [5]. Also, a recent
study demonstrated that two different TCRs, recognizing the same
HLA-B*07:02 restricted NY-ESO-1 peptide, could stabilize the
peptide in very different conformations [53]. Our study adds to
the story of flexibility during T-cell antigen recognition, through
a TCR induced shift in peptide primary anchor residue usage.
In summary, this study sheds new light on the mechanisms that
control T-cell recognition of an important tumor antigen and pro-
vides some explanations as to why therapeutic approaches have
not been successful in this system. We demonstrate that the MEL5
TCR, unlike other reported TCRs, was able to induce an anchor
residue switch in the dominant AAGIGILTV nonapeptide, enabling
recognition of the peptide in the optimal EAAGIGILTV-like confor-
mation. This TCR recognition mechanism likely contributes to the
ability of MEL5 to bind to A2-AAGwith stronger affinity than other
reported TCRs [23, 24]. These data, combined with our previous
findings [23], suggest that future therapeutic approaches should
focus on the selection of MEL5-like TCRs for optimal tumor recog-
nition. Finally, we reveal an extended mechanism of flexibility at
the TCR–pMHC interface that contributes to our understanding of
the molecular rules that govern T-cell antigen recognition.
Materials and methods
Generation of MEL5 TCR and α24β17 TCR and cell
culture
The MEL5 TCR was derived from the MEL5 CD8+ T-cell clone
specific for HLA-A*02:01 MART-126-35 and is previously described
[27, 54]. The α24β17 TCR, a high-affinity version of the MEL5
TCR, was generated by phage display as described previously [55].
Melanoma cell lines Mel562 (HLA-A2+), Mel624 (HLA-A2+),
and SK-MEL-28 (HLA-A2neg), breast adenocarcinoma MDA-MB-
231(HLA-A2+), and lymphoblast cell line T2 (HLA-A2+) were
obtained from laboratory stocks. All cell lines were cultured in
RPMI 1640 supplemented with 10% fetal bovine serum (FBS),
penicillin/streptomycin, and L-glutamine (all from Gibco, Paisley,
UK), and routinely tested for Mycoplasma infection, and found
negative (MycoAlertTM, Mycoplasma Detection Kit, Lonza).
Generation of TCR-transduced T cells
TCR transduced T-cells were generated as described previously
[56]. In brief, the following TCRs were codon optimized, syn-
thesized (GeneArtTM, Thermo Fisher Scientific) and cloned into a
third generation lentiviral vector pELNS (kindly provided by James
Riley, University of Pennsylvania, PA): MEL5 [27], MEL187.c5
[41], and DMF4 [57]. TCR-α and TCR-β chains, as well as rat CD2
marker gene were separated with self-cleaving 2A sequences [58]
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to ensure their stoichiometric expression. Lentiviral particles were
generated in HEK293T cell line by calcium phosphate transfection
of TCR-encoding pELNS plasmid together with packaging plas-
mids pRSV-Rev, pMDLg/pRRE, and envelope plasmid pMD2.G.
Prior to T-cell transduction, lentiviral particles were concentrated
100× by ultracentrifugation.
PBMCs were isolated from healthy donor buffy coats (Welsh
Blood Service, Pontyclun, UK) in accordance with local ethi-
cal approval and national legislation. PBMC isolation was per-
formed by Lymphoprep (Axis Shield, Olso, Norway) density gra-
dient centrifugation using SepMate tubes (STEMCELL Technolo-
gies, Vancouver, BC, Canada). CD8+ T cells were isolated from
three healthy donors’ PBMC using magnetic CD8MicroBeads (Mil-
tenyi Biotec) according to manufacturer’s recommendations. T
cells were then activated with CD3/CD28 beads (Dynabeads R©
Human T-Activator, Thermo Fisher Scientific) at three beads to
one T-cell ratio for 24 h prior to lentiviral transduction. Concen-
trated lentiviral particles were then added to T cells in presence
of 5 μg/mL polybrene (Santa Cruz Biotech). T cells were cultured
in T-cell media, composed of RPMI 1640 supplemented with 10%
FBS, penicillin/streptomycin, L-glutamine, 10 mM HEPES, 1 mM
sodium pyruvate, 1× nonessential amino acids, 25 ng/mL IL-15
(Peprotech, Rocky Hill, NJ), and 200 IU IL-2 (Prometheus, San
Diego, CA). On day 10 post transduction, T cells that had taken
up lentivirus were purified using anti-rat CD2 PE-conjugated anti-
body (OX-34, Biolegend) followed by anti-PE MicroBeads (Mil-
tenyi Biotec). On day 14, T cells were expanded in T-cell media
containing 20 IU/mL IL-2 and in presence of allogeneic irradiated
feeder cells from three donors and 1 μg/mL phytohemagglutinin
as described previously [59]. From day 14 post expansion, T cells
were used for functional experiments without cryopreservation.
In all functional assays, TCR-transduced T cells were >90% CD8+
rat CD2+. T-cell viability was routinely measured by Trypan blue
exclusion counting prior to functional experiments. Cell viability
was never below 90%.
Functional T-cell assays
T cells were rested for 24 h prior to functional assays in RPMI
1640 medium supplemented with 5% FBS. All functional assays
were performed in this medium. Flow cytometry: 50 000 T cells
were co-incubated with 50 000 cancer cells in presence of 30 μM
TNF processing inhibitor (TAPI-0, Sigma–Aldrich) and anti-TNF
antibody (cA2, Miltenyi Biotec) for 5 h. Following co-incubation,
cells were washed with PBS and stained with LIVE/DEAD Vio-
let Fixable Dead Cell stain (Life Technologies), as well as anti
CD3-PerCP (BW264/56, Miltenyi Biotec), anti-CD8 (BW135/80,
Miltenyi Biotec), and anti-rat CD2 antibodies (OX-34, Biolegend).
The cells were gated on lymphocytes based on forward and side
scatter, followed by sequential gating to include only viable CD8+
cells (and rCD2+, in case of TCR transduced cells). A minimum of
5000 live events were acquired on FACS Canto II (BD Biosciences),
and the analysis was performed using FlowJo software (TreeStar
Inc, Ashland, OR) and GraphPad Prism.
Enzyme-linked immunosorbent assay
A total of 30 000 T-cells were incubated with 30 000 T2 cells in
presence of titrated concentrations of ELAGIGILTV, EAAGIGILTV,
and AAGIGILTV peptides for 18 h. T cells incubated alone or with
10 μg/mL phytohemagglutinin were used as negative and positive
controls, respectively, to determine the maximum response. Fol-
lowing co-incubation, concentration of secreted MIP-1β and TNF
were measured using Human MIPβ or TNF DuoSet kit (R&D Sys-
tems), according to manufacturer’s recommendations. The exper-
iment was performed in duplicate. Data analysis was performed
in GraphPad Prism.
Cloning, expression, and refolding of proteins
The TCR-α and TCR-β chains as well as the MHC class I α-chains
(tagged and not tagged with a biotinylation sequence) and β2m
sequences were cloned into the pGMT7 expression vector under
the control of the T7 promoter using BamH1 and EcoR1 restric-
tion sites as described previously [60–62]. All sequences were
confirmed by automated DNA sequencing.
The TCR-α and TCR-β chains, the HLA-A*02:01 α chains, and
β2m were expressed separately, without posttranslational modi-
fication, as insoluble inclusion bodies in competent Rosetta DE3
Escherichia coli cells (Merk) using 1 mM IPTG as described previ-
ously [60–62].
For a 1 L TCR refold, 30 mg TCR-α chain was incubated at
37°C for 30 min with 10 mM DTT and added to cold refold buffer
(50 mM TRIS pH 8.1, 2 mM EDTA, 2.5 M urea, 6 mM cysteamine
hydrochloride, and 4 mM cystamine). After 30 min, 30 mg TCR-β
chain, also incubated at 37°C for 30 min with 10 mM DTT, was
added. For a 1 L pMHC-I refold, 30 mg HLA-A*02:01 α-chain was
mixed with 30 mg β2m and 4 mg of peptide at 37°C for 30 min
with 10 mM DTT. This mixture was then added to cold refold
buffer (50 mM TRIS pH 8.1, 2 mM EDTA, 400 mM L-arginine,
6 mM cysteamine hydrochloride, and 4 mM cystamine). TCR and
pMHC-I refolds were mixed at 4°C for >1 h and dialyzed against
10 mM TRIS pH 8.1 until the conductivity of the refolds was <2
mS/cm. All the refolds were then filtered, ready for purification
steps.
Refolded proteins were purified initially by ion exchange using
a Poros50HQTM column (Thermo Fisher Scientific Inc, MA, USA)
and finally gel filtered into crystallization buffer (10 mM TRIS
pH 8.1 and 10 mM NaCl) or BIAcore buffer (10 mM HEPES pH
7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) surfactant
P20) using a Superdex200HRTM column (GE Healthcare, Bucking-
hamshire, UK). Protein quality, either under nonreducing or reduc-
ing conditions, was analyzed by Coomassie-stained SDS-PAGE.
Protein crystallization and structure determination
Crystals were grown at 18°C by vapor diffusion via the sitting
drop technique. All crystallization-screening and optimization
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experiments were completed with an Art-Robbins Phoenix dis-
pensing robot (Alpha Biotech Ltd, U.K.). Two hundred nanoliters
of 10–15 mg/mL TCR–pMHC complex mixed at a 1:1 molar ratio
was added to 200 nL of reservoir solution. Intelli-plates were then
sealed and incubated at room temperature in a crystallization
incubator (18°C) (RuMed, Rubarth Apperate GmbH, Germany)
and analyzed for crystal formation crystal formation using the
Rock Imager 2 (Formulatrix, Bedford, MA USA). Crystals selected
for further analysis were cryoprotected with ethylene glycol to
25% and then flash cooled in liquid nitrogen in Litho loops
(Molecular Dimensions, UK). For MEL5-A2-AAG, optimal crystals
were obtained in TOPS [63] with 0.1 M HEPES pH 7.5, 25% PEG
4000, and 15% glycerol. For α24β17-A2-AAG, optimal crystals
were obtained in TOPS [63] with 0.1 M HEPES pH 7.0, 20% PEG
4000, and 15% glycerol.
Diffraction data were collected at several different beamlines
at the Diamond Light Source (Oxford, UK) using a Pilatus 2M
detector, a QADSC detector or a Rayonix detector. Using a rotation
method, 400 frames were recorded each covering 0.5° of rotation.
Reflection intensities were estimated with the XIA2 package [64,
65] and the data were scaled, reduced, and analyzed with SCALA
and the CCP4 package [66]. The TCR-pMHC complex structures
were solved with molecular replacement using PHASER [67]. The
model sequences were adjusted with COOT [68] and the models
refined with REFMAC5. Accession code MEL5-A2-AAG: PDB 6EQA
and α24β17-A2-AAG: PDB 6EQB.
pMHC biotinylation and surface plasmon resonance
analysis
Biotinylated pMHCs were prepared as described previously [69].
Binding analysis was performed using a BIAcore T100TM or a
BIAcore R© 3000 (GE Healthcare, Buckinghamshire, UK) equipped
with a CM5 sensor chip. Briefly, CM5 chip coupling solutions
containing 100 μL of 100 mM NHS and 100 μL of 400 mM
EDC were used to activate the chip prior to streptavidin bind-
ing. Approximately 5000 response units (RU) of streptavidin
(110 μL of 200 μg/mL in 10 mM acetate pH 4.5) was cova-
lently linked to the chip surface in all four flow cells and 100 μL
of 1 M ethanolamine hydrochloride was used to deactivate any
remaining reactive groups. Approximately 200–500 RU of pMHC
was attached to the CM5 sensor chip at a slow flow rate of
10 μL/min to ensure uniform distribution on the chip surface.
Combined with the small amount of pMHC bound to the chip sur-
face, this reduced the likelihood of off-rate-limiting mass trans-
fer effects. HLA-B*81:01-TPQDLNTML-Gag180-188 [70] and HLA-
B*51:01-TAFTIPSI-HIV-RT128-135 [71] were used as negative con-
trols. MEL5 was purified and concentrated to 120 μM and
α24β17 was purified and concentrated to 0.5 μM on the same
day of surface plasmon resonance analysis to reduce the likelihood
of TCR aggregation affecting the results.
For equilibrium and kinetic analysis with MEL5, 10 serial
dilutions (1/2) were prepared in triplicate for each sample and
injected over the relevant sensor chips at 25°C. MEL5 was injected
over the chip surface using kinetic injections at a flow rate of
45 μL/min. For the thermodynamics experiments, this method
was repeated at the following temperatures: 5, 10, 15, 20, 25,
and 30°C. Results were analyzed using BIAevaluation 3.1 (GE
Healthcare, Buckinghamshire, UK), Excel and Origin 6.0 software.
The equilibrium binding constant (KD) values were calculated
assuming a 1:1 interaction (A + B ↔ AB) by plotting specific
equilibrium-binding responses against protein concentrations fol-
lowed by nonlinear least squares fitting of the Langmuir binding
equation AB = B×ABmaxKD+B . The thermodynamic parameters were
calculated using the nonlinear van’t Hoff equation (RT ln KD =
H° – TS° + Cp°(T – T0) – TCp° ln (T/T0)) with T0 = 298 K.
For surface plasmon resonance analysis with α24β17, the
single-cycle kinetics method [72] was used. Five serial dilutions
(1/3) were prepared in duplicate for each sample and the TCR
was injected at 25°C at a flow rate of 45 μL/min for 200 s. The
dissociation time between each injection was 120 s and the dissoci-
ation time after the last injection was 3600 s. Association constant
(kon), dissociation constant (koff), and affinity constant (KD) were
estimated by global fitting of the data using BIAevaluation 3.1
software. For the thermodynamics experiments, this method was
repeated at the following temperatures: 5, 7, 12, 15, 19, 22, 25,
30, and 32°C. The thermodynamic parameters were calculated
using the nonlinear van’t Hoff equation with Origin 6.0 software.
NMR experiments
Solvent-suppressed 1H spectra (pulse program zgesgp) and 1H-13C
HSQC spectra (pulse program hsqcetgpsisp2; 13C spectral window
of 12.5–22.5 ppm) were acquired on a Bruker AVANCE III 600
MHz (1H) NMR spectrometer equipped with a QCI-P cryoprobe at
room temperature. HLA-A*02:01 was refolded as above using a
1:1 mixture of A(13C3)AGIGILTV and AAGIGILTV(15N,13C5). Half
of this solution was added to MEL5 TCR solution to form the
ternary complex, while half was added to an equivalent volume of
buffer tomaintain the binary complex. TheMEL5 TCR and A2-AAG
proteins were used at 1 mg/mL in PBS. Resonance assignments
were confirmed using a 2D (HC)CH-TOCSY experiment.
Rigidity analysis using FIRST software
Peptide rigidity was simulated using FIRST rigidity analysis [73]
to identify hydrophobic tethers between residues based on the
proximity of nonpolar heavy atom species, essentially aliphatic or
aromatic carbons. Hydrogen bonds were also identified based on
the proximity of polar H and acceptor atoms (O,N), and rated by
strength based on the donor–hydrogen–acceptor geometry, on an
energy scale from 0 to –10 kcal/mol. A rigidity analysis of the all-
atom input structure was carried out in FIRST using the “pebble
game” algorithm [74, 75], which matches degrees of freedom
against bonding constraints in the molecular framework of the
protein. Bonding constraints include covalent, hydrophobic and
polar (hydrogen bond and salt bridge) interactions. As the strength
C© 2019 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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of the polar interactions can be gauged from their geometry, the
results of the analysis depend on an “energy cutoff,” which selects
the set of polar interactions to include in the constraint network
[73]. Comparison of the cutoffs at which different features of a
protein complex become flexible thus provides information on the
relative rigidity and stability of these features. We report cutoff
values to a precision of 0.01 kcal/mol.
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